DPC-423 Bristol-Myers Squibb.
DPC-423 is a biphenylamine-containing amide which is under development by Bristol-Myers Squibb (formerly DuPont Pharmaceuticals) as a Factor Xa inhibitor for the potential treatment of thrombotic disorders [372092]. As of August 2000, DPC-423 was in phase I trials [380880]. DPC-423 was discovered as a result of SAR modifications of DuPont's SN-429, including replacement of the benzamidine moiety with a less basic benzylamine [398701]. Its 2-aminomethylphenyl analog DPC-602 is also under investigation for thrombotic disorders [402714].
Taglialatela
Maurizio
M
University of Naples Federico II, Department of Neuroscience, Italy. mtaglial@unina.it
D000818:Animals; D000990:Antithrombin III / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D018938:Caco-2 Cells; D002463:Cell Membrane Permeability; D004195:Disease Models, Animal; D004345:Drug Industry; D015507:Drugs, Investigational / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D065427:Factor Xa Inhibitors; D006801:Humans; D011720:Pyrazoles / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D013329:Structure-Activity Relationship; D013450:Sulfones / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D013927:Thrombosis / Q000188:drug therapy*
C421624:1-(3-(aminomethyl)phenyl)-N-(3-fluoro-2'-(methylsulfonyl)(1,1'-biphenyl)-4-yl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide; D015507:Drugs, Investigational; D065427:Factor Xa Inhibitors; D011720:Pyrazoles; D013450:Sulfones; D000990:Antithrombin III